Late Safety, Efficacy, and Cost-Effectiveness of a Zotarolimus-Eluting Stent Compared With a Paclitaxel-Eluting Stent in Patients With De Novo Coronary Lesions. 2-Year Follow-Up From the ENDEAVOR IV Trial

Martin B. Leon, David E. Kandzari, Eric L. Eisenstein, Kevin J. Anstrom, Laura Mauri, Donald E. Cutlip, Eugenia Nikolsky, Charles O'Shaughnessy, Paul A. Overlie, Ajay J. Kirtane, Brent T. McLaurin, Stuart L. Solomon, John S. Douglas, Jeffrey J. Popma

Research output: Contribution to journal › Article › peer-review

57 Scopus citations

Fingerprint

Dive into the research topics of 'Late Safety, Efficacy, and Cost-Effectiveness of a Zotarolimus-Eluting Stent Compared With a Paclitaxel-Eluting Stent in Patients With De Novo Coronary Lesions. 2-Year Follow-Up From the ENDEAVOR IV Trial'. Together they form a unique fingerprint.

Medicine & Life Sciences